79 results about "Broadly neutralizing antibody" patented technology

Embodiments of the present invention are directed to compositions and methods for anti-HIV (anti-CD4 binding site) broadly neutralizing antibodies having improved potency and breadth for neutralizing a range of HIV strains. Combinations of broadly neutralizing antibodies can also improve potency over a single antibody composition.

The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies may be characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided.

Embodiments of the present invention are directed to compositions and methods for anti-HIV (anti-CD4 binding site) broadly neutralizing antibodies having improved potency and breadth for neutralizing a range of HIV strains. Combinations of broadly neutralizing antibodies can also improve potency over a single antibody composition.

The invention belongs to the field of biology, and discloses a foot-and-mouth disease virus O-type inner broad-spectrum neutralizing swine monoclonal antibody and application thereof, the amino acid sequence of a heavy chain variable region of the monoclonal antibody is shown as SEQ ID NO.1, the amino acid sequence of a light chain variable region of the monoclonal antibody is shown as SEQ ID NO.2, the antigen key amino acid residue recognized by the monoclonal antibody is VP2 protein 77 site, and the amino acid sequence of the heavy chain variable region of the monoclonal antibody is shown as SEQ ID NO.1. The amino acid sequence of the light chain variable region of the monoclonal antibody is shown as SEQ ID NO.2. The site is located at a structural protein VP2B-C ring, is a conformational epitope, does not react with an A-type antigen, is an intra-strain broad-spectrum neutralizing antibody, and shows relatively strong neutralizing efficacy (IC50 is less than 5 [mu] g.mL <-1 >). Meanwhile, the invention also provides application of the monoclonal antibody.

The invention belongs to the technical field of biology, and particularly relates to a porcine epidemic diarrhea virus broad-spectrum neutralizing antibody and application thereof. A porcine epidemic diarrhea virus broad-spectrum neutralizing antibody 6G2 is screened, the virus neutralizing activity of the antibody is evaluated through a cell model, and it is found that the antibody can effectively block infection of G1a, G1b, G2a, G2b, G2c and S-INDEL (porcine epidemic diarrhea virus) gene subtype strains with high epidemic rate on cells. Further, animal infection experiments of pigs prove that the neutralizing antibody provided by the invention has good prevention and treatment effects on the porcine epidemic diarrhea virus, and has important significance on improving the capability of preventing and controlling porcine epidemic diarrhea in a pig farm.

The present application relates to epitope-targeted SIV and HIV vaccines. The invention provides novel envelope glycoproteins which may be utilized as HIV-1 vaccine immunogens, antigens for crystallization, and for identification of broadly neutralizing antibodies. The invention encompasses preparation and purification of immunogenic compositions which are formulated into vaccines of the present invention.

The present invention relates to anti-HIV antibodies. Also disclosed are related methods and compositions. HIV causes acquired immunodeficiency syndrome (AIDS), a condition in humans characterized by clinical features including wasting syndromes, central nervous system degeneration and profound immunosuppression that results in life-threatening opportunistic infections and malignancies. Since its discovery in 1981, HIV type 1 (HIV-1) has led to the death of at least 25 million people worldwide.

AAV vectors are ideally suited for long-term delivery of a combination of broadly neutralizing antibodies to achieve sterilizing immunity to HIV. Unfortunately, host immune responses to the delivered antibody have severely limited the efficacy. The TLR9 pathway has been identified in initiating adaptive immune responses against AAV and delivered bNAbs. To enhance this strategy, we validated Hydroxychloroquine, a known drug inhibitor of the TLR9 pathway, as a pretreatment to AAV delivery to avoid anti-drug antibody responses. TLR9 signaling inhibition was validated using a HEK-Blue hTLR9 reporter cell line and CpG stimulation. Hydroxychloroquine was also validated in a 3-macaque trial where AAV9-3BNC117 and AAV9-10-1074 were administered along with 3 doses of hydroxychloroquine once a week starting 1 week before AAV inoculation. Unlike historical controls, where 3BNC117 and 10-1074 expression is lost within the first 4-5 weeks, 2 macaques maintained 10-1074 expression and 1 macaque maintained 3BNC117 for the duration of the trial. Anti-3BNC117 antibodies were only observed in 2 of the 3 macaques and were significantly delayed. Anti-10-1074 antibody responses were a log lower than typically observed in historic controls. The use of hydroxychloroquine as a pretreatment for AAV inoculation is a promising strategy. The significant decrease in anti-10-1074 antibody levels and the successful delivery of 10-1074 in 2 macaques and 3BNC117 in 1 macaque was very encouraging. Extending the dosage of hydroxychloroquine beyond 3 doses may be sufficient to observe long-term bNAb expression in all animals and further decrease ADA responses. Together, these data suggest that the short-term treatment of hydroxychloroquine at the time of AAV inoculation has a meaningful impact on tolerance induction to our AAV-delivered bNAbs.

This invention belongs to the field of biotechnology, specifically relating to a broad-spectrum neutralizing antibody against porcine epidemic diarrhea virus (PEDV) and its applications. This invention screened a broad-spectrum neutralizing antibody against PEDV, 6G2. Cell model evaluation revealed that the antibody effectively blocked infection of cells by several highly prevalent PEDV genotypes: G1a, G1b, G2a, G2b, G2c, and S-INDEL. Further animal infection experiments in pigs demonstrated that the neutralizing antibody provided by this invention has good preventive and therapeutic effects against PEDV, which is of great significance for improving the ability of pig farms to control PEDV.

The invention belongs to the technical field of biological pharmacy, and particularly relates to a broad-spectrum neutralizing antibody of sand bay coronavirus and application of the broad-spectrum neutralizing antibody. The antibody is a combination of any one or more of KXD350, KXD352, KXD355 and KXD358, each of the KXD350, the KXD352, the KXD355 and the KXD358 comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region has three heavy chain CDRs, and the light chain variable region has three light chain CDRs. The four broad-spectrum neutralizing antibodies and the disclosed heavy chain and light chain variable region sequences provide a basis for construction of a sand bay coronavirus therapeutic neutralizing antibody with high affinity, high quality and strong specificity, and have high application value in prevention and control and treatment of coronavirus.

Disclosed are monoclonal antibodies, antigen binding fragments, and multi-specific antibodies that specifically bind a coronavirus spike protein, such as SARS-CoV-2. Also disclosed is the use of these antibodies and multi-specific antibodies for inhibiting a coronavirus infection, such as a SARS-CoV-2 infection. In addition, disclosed are methods for detecting a coronavirus, such as SARS-CoV-2, in a biological sample, using the disclosed antibodies and multi-specific antibodies.

The invention belongs to the field of biology, and discloses a broad-spectrum neutralizing porcine monoclonal antibody for foot-and-mouth disease virus type O and its application. The amino acid sequence of the heavy chain variable region of the monoclonal antibody is shown in SEQ ID NO.1, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO.2. The key amino acid residue of the antigen recognized by the monoclonal antibody is position 77 of the VP2 protein. The site is located in the VP2B-C loop of the structural protein and is a conformational epitope. The site does not react with type A antigen, is a broad-spectrum neutralizing antibody within the type, and exhibits a strong neutralizing efficacy (IC 50 <5μg·mL ‑1 ). At the same time, the present invention also provides the application of the monoclonal antibody.

The instant disclosure provides antibodies and antigen-binding fragments thereof that can bind to an influenza virus neuraminidase (NA) and can neutralize an influenza virus infection. Also provided are polynucleotides that encode an antibody, vectors that comprise such polynucleotides, host cells that can express the antibodies, related compositions, and methods of using the herein disclosed compositions to, for example, treat or prevent an influenza infection.

The invention provides broadly neutralizing antibodies directed to epitopes of Human Immunodeficiency Virus, or HIV. The invention further provides compositions containing HIV antibodies used for prophylaxis, and methods for diagnosis and treatment of HIV infection.

This invention belongs to the field of biomedical technology, specifically relating to an antigenic epitope peptide combination for a broad-spectrum novel coronavirus vaccine and its application. The antigenic epitope peptide combination of this invention includes a combination of viral spike protein Epi-I antigenic epitope peptides, a combination of viral spike protein Epi-II antigenic epitope peptides, and a combination of viral spike protein Epi-III antigenic epitope peptides. These antigenic epitope peptide combinations are obtained by screening spike protein epitopes from three broad-spectrum neutralizing antibodies against SARS-CoV-2, and can induce a broad-spectrum neutralizing antibody response in the host, used for the preparation of a broad-spectrum novel coronavirus vaccine. Using the antigenic epitope peptide combination of this invention, an antigenic epitope fusion protein L9 was obtained and prepared into a vaccine. The results of the examples show that the L9 vaccine has a better neutralizing effect against SARS-CoV-2 variants than the control group of the Wuhan strain of SARS-CoV-2 spike protein RBD, exhibiting good cross-neutralization.

The present disclosure relates to monoclonal human antibodies, or binding fragments thereof, directed against the CD4 binding site of human immunodeficiency virus HIV-1, pharmaceutical compositions comprising such monoclonal human antibodies, or binding fragments thereof, kits comprising such antibodies, or binding fragments thereof, and monoclonal antibodies or binding fragments thereof as well as pharmaceutical compositions and kits for use as medicaments and for the treatment or prevention of diseases caused by human immunodeficiency virus HIV-1.

The present disclosure provides antibodies and antigen-binding fragments that are capable of binding to RSV and / or MPV fusion glycoproteins and that are capable of neutralizing RSV and / or MPV infection. Also provided are polynucleotides encoding the antibodies, vectors comprising such polynucleotides, host cells capable of expressing these antibodies, related compositions, and methods of using the compositions disclosed herein, for example, to treat or prevent RSV and / or MPV infection.

The invention discloses a broad-spectrum neutralizing antibody W328-6E10 and an application of the broad-spectrum neutralizing antibody W328-6E10 in preparation of vaccines aiming at coronavirus. The invention provides an IgG antibody which is named as a W328-6E10 antibody and consists of a light chain and a heavy chain, cDR1, CDR2 and CDR3 in a heavy chain variable region in the heavy chain are sequentially shown as the 45 to 52 sites, the 70 to 77 sites and the 116 to 129 sites in SEQ ID NO: 1; cDR1, CDR2 and CDR3 in a light chain variable region in the light chain are sequentially shown as the 46th site to the 51st site, the 69th site to the 71st site and the 108th site to the 116th site in SEQ ID NO: 3. The W328-6E10 antibody not only has the effect of neutralizing the atypical pneumovirus, but also has broad-spectrum neutralizing activity on other coronaviruses. The invention has great application value for prevention and control of beta coronavirus, and can generate profound social significance.

The invention relates to an anti-HIV broad-spectrum neutralizing antibody with an ADCC effect and application of the anti-HIV broad-spectrum neutralizing antibody in treatment and / or prevention of HIV infected diseases. The antibody FD22 disclosed by the invention shows broad-spectrum and strong neutralizing capacity on different subtype HIV-1 pseudoviruses which are prevalent globally, and particularly shows excellent neutralizing activity on HIV-1AE and BC subtype strains which are prevalent widely in China. The antibody FD22 is an effective supplement for the existing HIV neutralizing antibody drug library, and can provide more comprehensive prevention and treatment choices for Chinese epidemic strains. Meanwhile, the antibody FD22 can promote expression of NK cell activating factors, activate NK cells and improve the degranulation effect of the NK cells, so that the killing effect of immune cells such as the NK cells on HIV infected cells is enhanced, and the potential of treating HIV infection is shown.

Methods of identifying virus antigens are provided. In particular the antigens induce broadly neutralizing antibodies in Hepatitis C virus infections. Compositions for inducing an immune response are identified by the methods described herein.

To provide a novel human monoclonal antibody against HIV-1.SOLUTION: The present disclosure relates to monoclonal human antibodies or binding fragments thereof that target the CD4 binding site of the human immunodeficiency virus HIV-1, a pharmaceutical composition comprising such monoclonal human antibodies or binding fragments thereof, a kit comprising such antibodies or binding fragments thereof, and the monoclonal antibodies or binding fragments thereof, the pharmaceutical composition, and the kit for use as a medicament and in the treatment or prevention of a disease caused by the human immunodeficiency virus HIV-1.SELECTED DRAWING: None

HIV treatment, and especially treatment of latent infected CD4 cells, can be significantly improved using a kick-and-kill approach that employs an immune stimulation component and / or HDAC inhibition as one treatment component, and that may also include a second component in which a vaccine composition, various NK cells, CAR-T cells, and / or broadly neutralizing antibodies are administered.

The invention discloses a broad-spectrum neutralizing antibody W328-6A1 aiming at coronavirus and application of the broad-spectrum neutralizing antibody W328-6A1. The invention provides an IgG antibody which is named as a W328-6A1 antibody and consists of a light chain and a heavy chain, cDR1, CDR2 and CDR3 in a heavy chain variable region in the heavy chain are sequentially shown as the 45 to 52 sites, the 70 to 76 sites and the 115 to 137 sites in SEQ ID NO: 1; cDR1, CDR2 and CDR3 in a light chain variable region in the light chain are sequentially shown as the 45 to 53 sites, the 71 to 73 sites and the 110 to 121 sites in SEQ ID NO: 3. The W328-6A1 antibody not only has the effect of neutralizing the atypical pneumovirus, but also has broad-spectrum neutralizing activity on other coronaviruses. The invention has great application value for prevention and control of beta coronavirus, and can generate profound social significance.

The present invention relates to monoclonal human antibodies or antigen-binding fragments thereof which are directed against the CD4 binding site of the human immunodeficiency virus HIV-1, a pharmaceutical composition comprising such monoclonal human antibodies or antigen-binding fragments thereof, a kit comprising such antibodies or antigen-binding fragments thereof, and the monoclonal antibodies or antigen-binding fragments thereof and the pharmaceutical composition and the kit for use as a medicament, and in the treatment or prevention of a disease caused by the human immunodeficiency virus HIV-1. The present invention further relates to nucleic acids encoding such antibodies or antigen-binding fragments thereof, expression vectors comprising such nucleic acids, host cells comprising such nucleic acids or expression vectors, and methods for the production of such antibodies or antigen-binding fragments thereof.

The present invention relates to monoclonal human antibodies or binding fragments thereof directed against the V3 glycan site of human immunodeficiency virus HIV-1, pharmaceutical compositions comprising such monoclonal human antibodies or binding fragments thereof, kits comprising such antibodies or binding fragments thereof, pharmaceutical compositions comprising such antibodies or binding fragments thereof, pharmaceutical compositions comprising such antibodies or binding fragments thereof, pharmaceutical compositions comprising such antibodies or binding fragments thereof, pharmaceutical compositions comprising such antibodies or binding fragments thereof, and pharmaceutical compositions comprising such antibodies or binding fragments thereof. And monoclonal antibodies or binding fragments thereof as well as pharmaceutical compositions and kits for use as medicaments and for the treatment or prevention of diseases caused by human immunodeficiency virus HIV-1.

The invention belongs to the field of biological medicine, and particularly relates to novel application of a functional regulator of xylosyltransferase 1 (XYLT1) in preparation of drugs for resisting human immunodeficiency virus (HIV) infection and / or resisting tumor immunotherapy. In-vitro experiments prove that up-regulation of expression or activity of XYLT1 can inhibit HIV virus replication (such as reduction of p24 antigen and virus infectivity) and enhance the curative effect of a broad-spectrum neutralizing antibody (such as 3BNC117); meanwhile, the XYLT1 can mediate the degradation of PD-L1 protein, relieve the inhibition on T cells and enhance the anti-tumor killing activity of CD8T cells. The invention provides a new target spot and a combined treatment strategy for immunotherapy of viral diseases and tumors.

The present invention relates to anti-HIV antibodies. Also disclosed are related methods and compositions. HIV causes acquired immunodeficiency syndrome (AIDS), a condition in humans characterized by clinical features including wasting syndromes, central nervous system degeneration and profound immunosuppression that results in life-threatening opportunistic infections and malignancies. Since its discovery in 1981, HIV type 1 (HIV-1) has led to the death of at least 25 million people worldwide.

Provided is in the field of immunology. Provided are broadly neutralizing antibodies against SARS-COV-2 variants, compositions and methods of prevention and treatment of SARS-COV-2 infection or transmission.